Onkologie 2020: 14(Suppl.G): 184-188 | DOI: 10.36290/xon.2020.102
Gastrinoma and its possible complications
- 1 Chirurgická klinika, Pardubická nemocnice, Nemocnice Pardubického kraje, a. s.
- 2 Interní klinika, Pardubická nemocnice, Nemocnice Pardubického kraje, a. s.
- 3 Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o., Pardubice
- 4 Oddělení klinické a radiační onkologie, Pardubická nemocnice, Nemocnice Pardubického kraje, a. s.
- 5 Oddělení patologie, Pardubická nemocnice, Nemocnice Pardubického kraje, a. s.
- 6 Fakulta zdravotnických studií Pardubice, Univerzita Pardubice
- 7 Oddělení nukleární medicíny, Chrudimská nemocnice, Nemocnice Pardubického kraje, a. s.
- 8 Lékařská fakulta Univerzita Karlova v Hradci Králové
Gastrinoma belongs to the group of neuroendocrine tumors (NET), which are characterised by secretion of hormonally active substances. The clinical finding is determined especially by the biological effect of the substance and is relatively characteristic. Nevertheless, the diagnostics is often very difficult and it takes months to years to specify the correct diagnosis. The article describes a case report of a patient with this tumor with an emphasis on important moments during diagnostic determination and possible pitfalls arising from conventional therapeutic procedures.
Keywords: gastrinoma, peptic ulcer disease, Zollinger-Ellison Syndrome, proton pump inhibitor, somatostatin analogs, Octreoscan.
Published: January 8, 2021 Show citation
References
- Cingam SR, Botejue M, Hoilat GJ, et al. Gastrinoma. [Updated 2020 Aug 28]. In: StatPearls [online]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. [cit. 09-10-2020]. Dostupné z: https://www.statpearls.com/articlelibrary/viewarticle/22083/
- Schubert M, Rehfeld JF. Gastric peptides - gastrin and somatostatin. Compr Physiol 2020; 10(1): 197-228. Dostupné z: https://onlinelibrary.wiley.com/doi/abs/10.1002/cphy.c180035
Go to original source... 
Go to PubMed... - Guarnotta V, Martini C, Davì MV, et al. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine 2018; 60(1): 15-27. [cit. 09-10-2020]. Dostupné z: doi: 10.1007/s12020-017-1420-4. Go to original source... Go to PubMed...
- Cho MS, Kasi A. Zollinger Ellison Syndrome. [Updated 2020 Jun 29]. In: StatPearls [online]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. [cit. 09-10-2020]. Dostupné z: https://www.statpearls.com/articlelibrary/viewarticle/31473/.
- Banasch M, Schmitz F. Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors. Wien Klin Wochenschr. 2007; 119(19-20): 573-578. Dostupné z: doi: 10.1007/s00508-007-0884-2. Go to original source... Go to PubMed...
- Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998; 228(2): 228-238. Dostupné z: doi: 10.1097/00000658-199808000-00013. Go to original source... Go to PubMed...
- Artiko V, Afgan A, Petrović J, et al. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC. Nucl Med Rev Cent East Eur. 2016; 19(2): 99-103. Dostupné z: doi: 10.5603/NMR.2016.0020. PMID: 27479786. Go to original source... Go to PubMed...
- Manoharan P, Lamarca A, Navalkissoor S, et al. Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). ESMO Open. 2020; 5(2): e000650. Dostupné z: doi: 10.1136/esmoopen-2019-000650 Go to original source... Go to PubMed...
- Hubbard H, Goodgame R. Evaluation of possible gastrinoma. MedGenMed 2007; 9(1): 31. Dostupné z: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924984/.
- Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011, Oct; 105(8): 1173-1175. Dostupné z: doi: 10.1038/bjc.2011.380 Go to original source... Go to PubMed...
- Vyzula R, Adámková Krákorová D, Arenberger P, et al. 27. Neuroendokrinní nádory. In: Modrá kniha České onkologické společnosti. 25. aktualizace. Brno: KAPCZ. Vydal Masarykův onkologický ústav. 2019: 196-201. Dostupné z: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/diagnostika-a-lecba/modra-kniha-cos/aktualni-vydani-modre-knihy/26-27-neuroendokrinni-nadory/.
- Wardlaw R, Smith JW. Gastric carcinoid tumors. Ochsner J. 2008; 8(4): 191-196. [cit. 09-10-2020]. Dostupné z: http://www.ochsnerjournal.org/content/ochjnl/8/4/191.full.pdf. Go to PubMed...
- Gut P, Czarnywojtek A, Bączyk M, et al. Clinical features of gastroenteropancreatic tumours. Prz Gastroenterol. 2015; 10(3): 127-134. Dostupné z: doi:10.5114/pg.2015.52346 Go to original source... Go to PubMed...
- Feliberti E, Hughes MS, Perry RR, et al. Gastrinoma. [Updated 2017 Jun 5]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [online]. South Dartmouth (MA): MDText.com, Inc.; 2000-. [cit. 10-11-2020]. Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK279075/.